An Update on the Management of Advanced Phase Chronic Myeloid Leukemia

Short, Nicholas J.; Senapati, Jayastu; Jabbour, Elias

doi:10.1007/s11899-023-00709-4

Curr Hematol Malig Rep

2023

DOI: 10.1007/s11899-023-00709-4

|View full text |Cite

An Update on the Management of Advanced Phase Chronic Myeloid Leukemia

Nicholas J. Short,

Jayastu Senapati,

Elias Jabbour

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia

Pamuk,

Ehrlich

2024

Cancers

View full text Add to dashboard Cite

Myeloid blast-phase chronic myeloid leukemia (MBP-CML) is a rare disease with a dismal prognosis. It is twice as common as lymphoid blast-phase CML, and its prognosis is poorer. Despite the success with tyrosine kinase inhibitors in the treatment of chronic-phase CML, the same does not hold true for MBP-CML. In addition to the Philadelphia chromosome, other chromosomal and molecular changes characterize rapid progression. Although some progress in elucidating the biology of MBP-CML has been made, there is need to discover more in order to develop more satisfactory treatment options. Currently, most common treatment options include tyrosine kinase inhibitors (TKIs) as monotherapy or in combination with acute myeloid leukemia-based intensive chemotherapy regimens. Some patients may develop resistance to TKIs via BCR-ABL1-dependent or BCR-ABL1-independent mechanisms. In this paper, we provide an overview of the biology of MBP-CML, the current treatment approaches, and mechanisms of resistance to TKIs. In order to improve treatment responses in these patients, more emphasis should be placed on understanding the biology of myeloid blastic transformation in CML and mechanisms of resistance to TKIs. Although patient numbers are small, randomized clinical trials should be considered.

show abstract

An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia

Pamuk,

Ehrlich

2024

Cancers

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

An Update on the Management of Advanced Phase Chronic Myeloid Leukemia

Cited by 1 publication

References 71 publications

An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia

An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia

Contact Info

Product

Resources

About